EICHOR
● Completed
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
Condition: Parkinson's Disease (PD) · Sponsor: AbbVie
About this study
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how safe and effective ABBV-951 is in adult participants with PD. Adverse events and change in disease activity is evaluated. ABBV-951 is an investigational (unapproved) drug containing Levodopa Phosphate/Carbidopa Phosphate (LDP/CDP) given as an infusion under the skin for the treatment of Parkinson's Disease. Adult participants with advanced PD and who have completed M15-736 or M20-339 study will be enrolled. Approximately 130 participants will be enrolled in the study in approximately 60 sites in the United States and Australia. Participants will receive continuous subcutaneous infusion (CSCI) (under the skin) of ABBV-951 for 96 weeks during the Primary Treatment Period and during the optional Extended Treatment Period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical and remote telephone assessments, blood tests, checking for side effects, and completing questionnaires.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (52)
| University of Alabama at Birmingham - Main /ID# 217814 | Birmingham, Alabama, United States | — |
| Usa Mitchell Cancer Institute /ID# 218467 | Mobile, Alabama, United States | — |
| Xenoscience, Inc /ID# 222515 | Phoenix, Arizona, United States | — |
| Muhammad Ali Parkinson Center /ID# 218609 | Phoenix, Arizona, United States | — |
| Movement Disorders Center of Arizona /ID# 218471 | Scottsdale, Arizona, United States | — |
| Neuro Pain Research Center /ID# 217720 | Fresno, California, United States | — |
| Loma Linda University Medical /ID# 217724 | Loma Linda, California, United States | — |
| University of California, Los Angeles /ID# 218460 | Los Angeles, California, United States | — |
| SC3 Research Group - Pasadena /ID# 223018 | Pasadena, California, United States | — |
| University of California, San /ID# 218595 | San Diego, California, United States | — |
| Duplicate_Cedars-Sinai Medical Center-West Hollywood /ID# 218607 | West Hollywood, California, United States | — |
| University of Colorado Hospital /ID# 218486 | Aurora, Colorado, United States | — |
+ 40 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04750226